Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
NMES vs GCS Symptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Ungraded |
NMES vs alternative prophylaxis PE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 1.31 [0.38, 4.48] | 2 studies · 126 participants | Low |
NMES vs GCS PE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.32 [0.01, 8.27] | 1 study · 36 participants | Low |
NMES vs GCS Total VTE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Ungraded |
NMES vs GCS Bleeding (major and minor) · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Ungraded |
NMES vs IPCD Total DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Low |
NMES vs IPCD Asymptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Ungraded |
NMES vs IPCD Symptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Ungraded |
NMES vs IPCD PE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Low |
NMES vs IPCD Total VTE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Ungraded |
NMES vs IPCD Bleeding (major and minor) · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Ungraded |
NMES vs alternative prophylaxis Total VTE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.92 [0.34, 2.52] | 1 study · 72 participants | Low |
NMES vs alternative prophylaxis Bleeding (major and minor) · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 6 studies · 415 participants | Ungraded |
NMES vs no prophylaxis Total DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.4 [0.23, 0.7] | 4 studies · 576 participants | Moderate |
NMES vs no prophylaxis Asymptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.32 [0.06, 1.62] | 1 study · 200 participants | Low |
NMES vs no prophylaxis Symptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.06 [0, 1.36] | 1 study · 160 participants | Low |
Fondaparinux plus vitamin K antagonist vs standard therapy Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 0.8 [0.43, 1.47] | 2 studies · 2658 participants | Moderate |
Idrabiotaparinux vs idraparinux All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 0.48 [0.18, 1.27] | 1 study · 757 participants | Low |
Idrabiotaparinux vs idraparinux Heparin‐induced thrombocytopenia ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Idrabiotaparinux vs idraparinux All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 0.92 [0.83, 1.02] | 1 study · 757 participants | Very low |
Low molecular weight heparin and idraparinux vs standard therapy Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 1.51 [0.26, 8.9] | 1 study · 263 participants | Very low |
Low molecular weight heparin and idraparinux vs standard therapy Major bleeding during the initial treatment · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin and idraparinux vs standard therapy Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 3.76 [0.5, 28.19] | 1 study · 659 participants | Very low |
Low molecular weight heparin and idraparinux vs standard therapy All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin and idraparinux vs standard therapy Heparin‐induced thrombocytopenia · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin and idraparinux vs standard therapy All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Idraparinux vs standard therapy Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 0.98 [0.64, 1.48] | 1 study · 2904 participants | Low |
Fondaparinux plus vitamin K antagonist vs standard therapy Major bleeding during the initial treatment · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 1.15 [0.39, 3.44] | 2 studies · 2645 participants | Moderate |
Idraparinux vs standard therapy Major bleeding during the initial treatment · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Idraparinux vs standard therapy Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 0.71 [0.34, 1.47] | 1 study · 2904 participants | Very low |
Idraparinux vs standard therapy All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 1.14 [0.69, 1.86] | 1 study · 2904 participants | Low |
Idraparinux vs standard therapy Heparin‐induced thrombocytopenia · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Idraparinux vs standard therapy All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 1.03 [1, 1.06] | 1 study · 2904 participants | Very low |
Fondaparinux plus vitamin K antagonist vs standard therapy Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 1.05 [0.64, 1.71] | 2 studies · 2645 participants | Moderate |
Fondaparinux plus vitamin K antagonist vs standard therapy All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 0.93 [0.45, 1.91] | 2 studies · 2645 participants | Moderate |
Fondaparinux plus vitamin K antagonist vs standard therapy Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Fondaparinux plus vitamin K antagonist vs standard therapy All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 0.84 [0.76, 0.93] | 1 study · 2192 participants | Very low |
Idrabiotaparinux vs idraparinux Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 0.72 [0.31, 1.69] | 1 study · 757 participants | Low |
Idrabiotaparinux vs idraparinux Major bleeding during the initial treatment ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Idrabiotaparinux vs idraparinux Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | RR 0.21 [0.06, 0.71] | 1 study · 755 participants | Low |
Hand‐assisted laparoscopic repair vs EVAR In‐hospital mortality · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | no estimate extracted | 1 study · 100 participants | Low |
Hand‐assisted laparoscopic repair vs EVAR Operative time (minutes) · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | no estimate extracted | 1 study · 100 participants | Low |
Hand‐assisted laparoscopic repair vs EVAR Major complications ‐ lower limb ischaemia (up to 12 months) · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | RR 0.5 [0.05, 5.34] | 1 study · 100 participants | Low |
Hand‐assisted laparoscopic repair vs EVAR Long‐term complications (12 months or longer if reported) · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | no estimate extracted | NR | No studies |
Hand‐assisted laparoscopic repair vs EVAR All‐cause mortality/survival (> 30 days) · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | no estimate extracted | NR | No studies |
Hand‐assisted laparoscopic repair vs EVAR Length of ICU stay (days) · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | no estimate extracted | NR | No studies |
Hand‐assisted laparoscopic repair vs EVAR Overall length of hospital stay (days) · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | no estimate extracted | 1 study · 100 participants | Low |
Intervention NR Number of attacks · primary Raynaud's phenomenon Calcium channel blockers for primary Raynaud's phenomenon (2016) · Cochrane | no estimate extracted | 7 studies · 296 participants | Moderate |
Intervention NR Duration of attacks · primary Raynaud's phenomenon Calcium channel blockers for primary Raynaud's phenomenon (2016) · Cochrane | no estimate extracted | 1 study · 16 participants | Very low |
Intervention NR Severity scores · primary Raynaud's phenomenon Calcium channel blockers for primary Raynaud's phenomenon (2016) · Cochrane | no estimate extracted | 6 studies · 291 participants | High |